▼ -39.02% Downside Potential
This price target is based on 1 analysts offering 12 month price targets for Mind Medicine (MindMed) in the last 3 months. The average price target is $2.00, with a high forecast of $2.00 and a low forecast of $2.00. The average price target represents a -39.02% upside from the last price of $3.28.
The current consensus among 1 polled investment analysts is to buy stock in Mind Medicine (MindMed).
Mind Medicine (MindMed) Inc., a psychedelic medicine biotech company, discovers, develops, and deploys psychedelic inspired medicines and therapies to address addiction and mental illness. The company is assembling a compelling drug development pipeline of innovative treatments based on psychedelic substances, including Psilocybin, LSD, MDMA, DMT, and an Ibogaine derivative, 18-MC. The company is headquartered in New York, New York.